Abstract. Acute liver failure, i.e., the fatal deterioration of liver function, is the most common indication that emergency liver transplantation is necessary. Moreover, in the USA, drug-induced liver injury (DILI), including acetaminophen (APAP)-induced hepatotoxicity, is the main cause of acute liver failure. Matching a donor for liver transplantation is extremely difficult, and thus the development of a novel therapy for DILI is urgently needed. Following recent approval by the FDA of the proteasomal inhibitor bortezomib, its therapeutic effects on various human diseases, including solid and hematologic malignancies, have been validated. However, the specific action of proteasomal inhibition in cases of DILI had not been elucidated prior to this study. To examine the effects of proteasomal inhibition in DILI experimentally, male C56Bl/6 mice were injected with 1 mg bortezomib/kg before APAP treatment. Bortezomib not only alleviated APAP-induced hepatotoxicity in a time-and dose-dependent manner, it also alleviated CCl 4 -and thioacetamide-induced hepatotoxicity. We also noted that bortezomib significantly reduced cytochrome P450 2E1 (CYP2E1) expression and activity in the liver, which was accompanied by the induction of endoplasmic reticulum (ER) stress. In addition, bortezomib decreased hepatocyte nuclear factor-1α-induced promoter activation of CYP2E1 in Hep3B cells. By contrast, another proteasome inhibitor, MG132, did not cause ER stress and did not markedly affect CYP2E1 enzyme activity. Liver injury induced by APAP was aggravated by MG132, possibly via elevation of connexin 32 expression. This study suggests that proteasome inhibition has different effects in cases of DILI depending on the specific inhibitor being used. Furthermore, results from the mouse model indicated that bortezomib, but not MG132, was effective in alleviating DILI. ER stress induced by proteasome inhibition has previously been shown to exert various effects on DILI patients, and thus each available proteasomal inhibitor should be evaluated individually in order to determine its potential for clinical application.
Introduction
Drug-induced liver injury (DILI) is the most frequent cause of acute liver failure (1); of various drugs, acetaminophen (APAP) overdose accounts for approximately one-half of all cases of acute liver failure in the USA and the UK (2) . Acute liver failure suddenly affects young, otherwise healthy individuals, and is associated with an extremely high rate of mortality, and is the most frequent cause of emergency liver transplantation (1) . Drug-induced hepatotoxicity is usually caused by the formation of drug metabolites, which are often formed by the action of cytochrome P450 2E1 (CYP2E1; EC 1.14.13.n7), which transforms various chemicals into reactive metabolites. For example, APAP is converted by CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI), an electrophilic metabolite that binds to cysteine groups in proteins (3), depletes glutathione (GSH), and causes respiratory dysfunction and reactive oxidative stress (4) . Since finding a matching donor for liver transplantation is not always easy, novel therapies for treating DILI are urgently needed.
The proteasome is a multisubunit enzyme complex that degrades ubiquitin-tagged proteins; it plays a critical role in the regulation of proteins that control cell-cycle progression and apoptosis. Consequently, it has become an important target for anticancer therapy (5) . In in vitro experiments and in animal studies, the inhibition of the proteasome, either alone or in combination with conventional chemotherapeutic agents, demonstrated antitumour effects against numerous tumour types (5). In 2008, bortezomib (VELCADE; formerly, PS-341, LDP-341, and MLN341) was approved by the US Food and Drug Administration (FDA) as a therapeutic agent for multiple myeloma (6) . Recently, the therapeutic potential of bortezomib has been re-evaluated, and it has been reported that the compound is therapeutically effective for various diseases, such as tumours (7) , congenital erythropoietic porphyria (8) , and graft-versus-host disease (9) .
To investigate the role of the proteasome and the effects of its inhibition on DILI, we examined the effects of two proteasome inhibitors, bortezomib and MG132, on drug-and chemicalinduced hepatotoxicity. Interestingly, bortezomib alleviated APAP-induced hepatotoxicity, whereas MG132 had the opposite effect. In addition, bortezomib treatment decreased liver damage induced by CCl 4 or thioacetamide (TAA) and significantly decreased hepatic CYP2E1 transcription, leading to diminished enzyme activity. Results of the present study suggest that clinical treatment with bortezomib may be useful for alleviating DILI and possibly other forms of acute liver disease.
Materials and methods

Materials.
Bortezomib was purchased from Biovision (Mountain View, CA, USA). APAP, CCl 4 , TAA, MG132, sodium 4-phenylbutyrate (4-PBA), and 2-aminoethyl diphenylborinate (2-APB) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The primary antibodies used in this study were anti-CYP2E1 (AB1252; Millipore, Bedford, MA, USA), anticonnexin 32 (CX32; 35-8900; Invitrogen, Carlsbad, CA, USA), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; MAB374) (Millipore, Billerica, MA, USA), anti-binding immunoglobulin protein (BiP; 3177; Cell Signaling Technology, Beverly, MA, USA), anti-CCAAT-enhancer-binding protein homologous protein (CHOP; 5554; Cell Signaling Technology) and anti-β-actin (A5316; Sigma-Aldrich).
Animals. Male C57BL/6J mice, which were 6-8 weeks of age, were purchased from Orient Bio, Inc. (Seoul, Korea) and housed under special pathogen-free conditions. All animals were treated in accordance with the Animal Care Guidelines of Ewha Womans University. To induce hepatotoxicity, mice were injected intraperitoneally with the following: APAP (350 or 500 mg/kg), TAA (200 mg/kg), or CCl 4 (2 ml/kg), as described previously (10) . Before being injected, mice were fasted overnight. To inhibit the proteasome, bortezomib was injected twice: first at 12 h (1 mg/kg) and then at 1 h (1 mg/kg) prior to the injection of APAP, as previously described (11) . The inhibitor MG132 was injected (5 mg/kg) twice: first at 12 h and then at 1 h prior to the administration of APAP, as previously described (12, 13) . In some cases, different doses of bortezomib (0-1 mg/kg) were injected twice: first at 12 h and then at 1 h prior to the administration of APAP, and 1 mg/kg bortezomib was injected at different times prior to the administration of APAP. For the inhibition of gap junctions, 2-APB (20 mg/kg) was injected 2 h prior to the administration of APAP. DMSO-treated mice were used as the relevant control group. Each group consisted of 4-6 mice. For liver extraction, the mice were sacrificed at 0, 2, 4 6 h after the APAP injection and, at 24 h after the TAA or CCl 4 injection. The livers were then perfused with PBS to remove the blood via portal vein.
Cell culture. Human hepatocarcinoma Hep3B cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated foetal bovine serum, penicillin, and streptomycin (Gibco, Carlsbad, CA, USA). Cells were maintained at 37˚C in a humidified atmosphere containing 5% CO 2 . Prior to RNA extraction for expression studies or luciferase assays, cells were treated with bortezomib (10-250 nM) (14, 15) in serum-free medium for 15 h. To reduce ER stress, 4-PBA (1-5 mM) was added 1 h before bortezomib treatment.
Serum enzyme marker measurement. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured by the Korean Animal Clinical Research Center (Guri, Korea) using a Hitachi 7020 automatic biochemical analyser (Hitachi, Tokyo, Japan).
Reverse transcription-quantitative PCR (RT-qPCR).
Total mRNA from the liver tissues was extracted using an RNeasy Mini kit (Qiagen, Valencia, CA, USA), and cDNA was prepared from the mRNA using a Verso cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Primer sets are described in Table I . Relative gene expression was calculated as 2 -∆∆Ct by quantitative PCR, using the SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) and an ABI PRISM 7500 Sequence Detection system (Applied Biosystems) (16, 17) .
Western blot analysis. Liver tissues were lysed in radioimmunoprecipitation assay buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS] containing 50 mM NaF, 2 mM Na 3 VO 4 , and protease and phosphatase inhibitors (Sigma-Aldrich). Protein concentration was quantified using Bradford assay reagent (BioRad Laboratories, Hercules, CA, USA). Protein samples (40 µg) were subjected to SDS-polyacrylamide gel [8% (w/v)] electrophoresis and then transferred to nitrocellulose membranes. Membranes were incubated with primary antibodies followed by peroxidase-conjugated secondary antibodies (111-035-003 and 115-035-003; Jackson ImmunoResearch, West Grove, PA, USA) after blocking with 5% (w/v) BSA in 20 mM Tris-HCl at pH 7.5, 500 mM NaCl, and 0.1% (v/v) Tween-20. The immunocomplexes were detected by chemiluminescence using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and detected with a Bio-Imaging Analyzer (LAS-4000; Fuji, Tokyo, Japan).
Hematoxylin and eosin (H&E) staining. Liver tissues were fixed in 4% (w/v) paraformaldehyde, embedded in paraffin, sectioned at 4-µm thickness, and then stained with H&E using standard methods. Briefly, following deparafinization, the sections were stained with hematoxylin (Sigma-Aldrich) and then destained with acid ethanol (1 ml hydrochloric acid + 99 ml 70% ethanol). After washing with tap water, sections were stained with eosin (Sigma-Aldrich).
Measurement of GSH levels. Levels of GSH in the fresh liver were measured using a GSH assay kit (Biovision) according to the manufacturer's instructions. Briefly, 40 mg of liver tissues were homogenized with cold glutathione assay buffer, and 6 N perchloric acid was added. The samples were then precipitated with 3 N potassium hydroxide, and then centrifuged for 2 min at 13,000 x g. The neutralized samples were incubated with the o-phthalaldehyde probe and glutathione assay buffer for 40 min to detect reduced GSH. Fluorescence was deteced using a microplate fluorescence reader (BioTek Synergy H1; BioTek, Winooski, VT, USA).
Measurement of CYP2E1 enzyme activity.
In order to measure CYP2E1 activity, the rate of transformation of p-nitrophenol to p-nitrocatechol was analysed with isolated hepatic microsomes, as described previously (18, 19) . Briefly, the liver microsomes were incubated at 37˚C in assay buffer containing potassium phosphate buffer (50 mM, pH 7.4), NADPH (1 mM) and p-nitrophenol (0.1 mM), at the final concentrations indicated. After 20 min, the reactions were terminated by the addition of 0.6 N perchloric acid, and centrifuged at 10,000 x g for 5 min. Subsequently, 6 N sodium hydroxide was added to the supernatant, and the absorbance was measured at 546 nM using a microplate reader (BioTek Synergy H1; BioTek).
Reporter plasmid construct containing CYP2E1 gene promoter. In the present study, a 540-bp human CYP2E1 gene promoter using 5'-TAGGTACCCAGAAGTGAGATTCC TGTTCT-3' and 5'-CCCAAGCTTTGCCGATGGGGCTCC ACTCT-3' as primers was subcloned into the corresponding restriction sites of the luciferase reporter pGL3-basic vector (Promega, San Luis Obispo, CA, USA), as described in a previous study (20) . The underlined letters denote the corresponding restriction sites, KpnI and HindIII The subcloned sequences were verified by DNA sequence analyses.
Luciferase assay. The luciferase assay was performed with the Dual-Luciferase Reporter assay system (Promega) as previously described (21) . Reporter plasmid containing the CYP2E1 promoter region was transfected into Hep3B cells using Metafectene transfection reagent (Biontex, San Diego, CA, USA USA), and pRL-cytomegalovirus promoter (Renilla luciferase vector; Promega) was co-transfected to normalise the transfection efficiency. If necessary, pcDNA5/FRT/HNF-1α, obtained from Addgene (Addgene plasmid 31104), or its control vector pcDNA5/FRT/TO was transfected. After 24 h, each well was treated with bortezomib or 4-PBA, as indicated in the figure legends. Cells were lysed using Promega lysis buffer (Promega). Firefly and Renilla luciferase activities were measured sequentially in the same sample using a GloMax™ 20/20 Luminometer (Promega). Luciferase activities were normalised by dividing the firefly luciferase activity by the Renilla luciferase activity.
Statistical analysis.
Values are expressed as the means ± SEM. Statistical significance was determined using the Student's t-test, and a p-value <0.05 was considered to indicate a statistically significant difference.
Results
Bortezomib treatment alleviates APAP-induced hepatotoxicity in a time-and dose-dependent manner.
In order to determine the effect of bortezomib on DILI induced by APAP, we injected bortezomib intraperitoneally twice: first at different time points (1 mg/kg) (as indicated in Fig. 1A ) and then at 1 h (1 mg/kg) prior to the administration of APAP. Injecting 500 mg/kg APAP markedly elevated serum AST and ALT (Fig. 1) . When bortezomib was injected 2 h before APAP administration, serum AST and ALT levels were greatly elevated, similar to the DMSO-treated group (Fig. 1A) . Treatment with bortezomib for more than 3 h was needed to diminish the APAP-induced hepatotoxicity, as indicated by decreased serum AST and ALT levels and H&E staining (Fig. 1A and C) . In addition, bortezomib decreased APAP-induced hepatotoxicity in a dose-dependent manner, and this protective effect was noted at concentrations greater than 0.063 mg bortezomib/kg (Fig. 1B and D) .
Bortezomib treatment diminishes hepatotoxicity induced by other chemicals. Since the toxic mechanism differs between various drugs and chemicals, we investigated whether bortezomib treatment also protects against liver damage caused by other chemicals. Surprisingly, bortezomib treatment also alleviated CCl 4 -and TAA-induced hepatotoxicity (Fig. 2) . Thus, we posit that the common toxic mechanism of all three chemicals involves CYP2E1 (22) (23) (24) or gap junction function (25) .
Bortezomib decreases CYP2E1 enzyme expression and activity. GSH is an important antioxidant that detoxifies NAPQI by conjugation, and GSH depletion leads to toxic cascades of NAPQI (3, 4) . Basal levels of GSH did not differ significantly between DMSO-and bortezomib-treated mice (Fig. 3A) . Although GSH was markedly decreased in both DMSO-and bortezomib-treated groups following APAP administration, GSH levels remained higher at all time-points in bortezomib-versus DMSO-treated animals (Fig. 3A) .
Lower GSH depletion in bortezomib-treated mice implies the decreased formation of NAPQI. Since NAPQI is transformed by CYP2E1, we subsequently measured CYP2E1 expression by both RT-qPCR (Fig. 3B ) and western blot analysis (Fig. 3C) . Bortezomib treatment significantly decreased CYP2E1 transcription (Fig. 3B) , which resulted in lower CYP2E1 protein levels (Fig. 3C ). In addition, CYP2E1 enzymatic activity was significantly lower in the livers of bortezomib-treated versus control mice (Fig. 3D) . Therefore, we conclude that the decreased CYP2E1 enzyme activity caused by bortezomib administration alleviates liver damage induced by APAP, CCl 4 , and TAA exposure. This is in agreement with results of previous studies, in which a CYP2E1 deficiency prevented hepatotoxicity induced by these three chemicals (22) (23) (24) .
Bortezomib diminishes hepatocyte nuclear factor (HNF)-1α-induced CYP2E1 transcription.
In order to confirm whether bortezomib regulates CYP2E1 transcription, we transfected a hepatocyte cell line (Hep3B cells) with the reporter plasmid containing the CYP2E1 gene promoter region, and performed luciferase assays. Bortezomib treatment significantly decreased CYP2E1 promoter activity by itself (Fig. 4A) as well as HNF-1α-induced CYP2E1 promoter activity (Fig. 4B) . HNF-1α is the main transcription factor which positively regulates CYP2E1 gene transcription (26) (27) (28) .
Bortezomib induces endoplasmic reticulum (ER) stress in the liver, which partially contributes to decreased CYP2E1 levels.
Since bortezomib can lead to ER stress in vitro (29, 30) , which can induce decreased CYP2E1 mRNA levels (31), we next investigated whether bortezomib administration also causes ER stress in the liver in vivo. We examined altered levels of several proteins that were reported to be induced during ER stress. BiP, also referred to as glucose-regulated protein 78, is a central regulator of ER stress (32), and CHOP is one of the most highly induced transcription factors during ER stress (33). Bortezomib injections markedly elevated hepatic mRNA and protein levels of BiP and CHOP, indicating the in vivo induction of ER stress (Fig. 5) . IRE-1α protein expression was also increased 12 h after bortezomib treatment (Fig. 5C ). Subsequently, we used 4-PBA to confirm whether ER stress is directly involved in bortezomib-induced CYP2E1 decrement. Treatment with 4-PBA (5 mM), which is reported to decrease ER stress (34) , partially recovered CYP2E1 luciferase activity decreased by bortezomib treatment (Fig. 6) . Therefore, bortezomib-induced ER stress partially contributes to decreased CYP2E1 levels.
Protective effect of bortezomib on APAP-induced hepatotoxicity is not derived from direct inhibition of the proteasome.
In the present study, in order to investigate whether this effect of bortezomib is due to proteasome inhibition, we injected MG132, another well-known proteasome inhibitor, before APAP administration. By contrast to bortezomib treatment ( Fig. 7A and B) , MG132 aggravated APAP-induced hepatotoxicity, as demonstrated by elevated serum AST and ALT levels (Fig. 7C ) and by enhanced H&E staining (Fig. 7D) . These results suggest that the protective effect of bortezomib on APAP-induced hepatotoxicity is not derived from direct inhibition of the proteasome.
Proteasome inhibitor MG132 does not induce hepatic ER stress.
Since we noted that MG132, a second proteasome inhibitor, aggravated APAP-induced liver injury, by contrast with bortezomib ( Fig. 1) , we subsequently examined the effect of MG132 on CYP2E1 expression and ER stress. Unlike treatment with bortezomib, hepatic mRNA levels of CYP2E1 were not diminished upon MG132 administration (Fig. 8A) , and we also noted relatively unaltered CYP2E1 enzyme activity upon administration of MG132 (Fig. 8B ). In addition, it was demonstrated that MG132 administration did not induce ER stress, as indicated by unaltered mRNA levels of BiP and CHOP ( Fig. 8C and D) .
MG132, but not bortezomib, increases CX32 levels, which increases hepatotoxicity. In addition to CYP2E1 enzyme activity, it has previously been suggested that the common toxic mechanism of all three chemicals (APAP, TAA, and CCl 4 ) may also involve gap junctions (10, 25, 35, 36) , since gap junctions have been reported to play a critical role in the propagation of hepatotoxicity of all three chemicals used in the present study; ablation of CX32 (a key protein in hepatic gap junctions) significantly protects against DILI (10, 25, 35, 36) . Thus, we examined CX32 levels. Notably, MG132 administration significantly increased CX32 protein expression (Fig. 9A) , possibly by inhibiting its degradation, and 2-APB, a gap junction inhibitor, abolished MG132-aggravated APAP-induced liver damage (Fig. 9B) . Unexpectedly, bortezomib decreased CX32 expression, as well as CX43 mRNA levels ( Fig. 9C  and D) . Therefore, the opposite effects of bortezomib and MG132 on CX32 levels may contribute to the different impacts of bortezomib and MG132 on DILI.
Discussion
Protein metabolism, including both synthesis and degradation, is crucial for cellular homeostasis. Eukaryotic cells possess three different systems which are necessary for protein degradation: mitochondrial proteases, which degrade the majority of mitochondrial proteins; lysosomal proteases, which degrade membrane and endocytosed proteins; and the ubiquitin-proteasome system, which degrades the vast majority (80-90%) of intracellular proteins (37) . The proteasome system has emerged Figure 6 . Sodium 4-phenylbutyrate (4-PBA) partially recovered diminished cytochrome P450 2E1 (CYP2E1) promoter activity caused by bortezomib in vitro. Hep3B cells were transfected with a reporter plasmid containing the CYP2E1 promoter region with or without hepatocyte nuclear factor-1α (HNF-1α), and 4-PBA at the indicated concentrations was added for 1 h before bortezomib treatment. Relative luciferase activity was calculated as the ratio of firefly luciferase activity to Renilla luciferase activity in the same sample. Values are expressed as the means ± SEM (n=4). Data are representative of four independent experiments that provided similar results. * p<0.05. as a master regulator of diverse cellular processes, including cell cycle, survival, and apoptosis, and plays a critical role in many diseases, such as cancer (38) and neurodegenerative (39) and cardiovascular diseases (37) . In the present study, we demon- strated that the FDA-approved proteasome inhibitor bortezomib is effective at preventing drug-and chemical-induced acute liver injury via the regulation of CYP2E1 expression. Hepatic CYP2E1 levels were markedly decreased upon bortezomib treatment. Since CYP2E1 degradation involves the ubiquitin-proteasome pathway (40, 41) , the protective effect of bortezomib on drug-and chemical-induced liver injury seems attributable to a different mechanism than proteasome inhibition. Although bortezomib was originally developed as a proteasome inhibitor, other distinct mechanisms of bortezomib have been uncovered. One of these is ER stress (29, 30) , which, in turn, induces IRE-1α-mediated degradation of CYP2E1 mRNA (31) . In the present study, ER stress induced by bortezomib treatment also played a role in decreased CYP2E1 transcription, which may alleviate DILI. The main governing factor of CYP2E1 transcriptional regulation is HNF-1α (26-28), and we noted that bortezomib significantly decreased HNF-1α-induced promoter activation of CYP2E1, and 4-PBA treatment partially recovered bortezomib's inhibition of CYP2E1 promoter activity. Therefore, ER stress plays a role in bortezomib-induced CYP2E1 decrement. Although MG132 was reported to induce ER stress in vitro (42) , its administration in vivo did not cause ER stress. Although questions such as whether the relatively long half-life of bortezomib (43) contributes to the different phenotype in vivo compared with MG132, or, rather, a distinct mechanism of bortezomib other than proteasome inhibition may exist, require further study, the protective effect of bortezomib on DILI is noteworthy, considering its current clinical use.
Interestingly, the effects of two well-known proteasome inhibitors, bortezomib and MG132, exerted opposite effects on APAP-induced liver injury. Since proteasome inhibition potentiates CYP2E1-mediated toxicity in HepG2 cells by elevating CYP2E1 levels (44), the aggravating effects of MG132 on APAP-induced liver damage are predictable. However, since no marked change was observed in CYP2E1 enzyme activity, the aggravating effect of MG132 on APAP-induced liver damage appears to be due to some other mechanism, such as gap junction elevation; this was confirmed by elevation of CX32 levels. Gap junctions have recently been implicated as important players in amplifying DILI (25, 36) . Gap junction channels are composed of CX proteins and play an important role in intercellular communication and in the propagation of liver toxicity and inflammation (10, 25, 36) . Ablation or decreased levels of CX32, a major hepatic gap junction protein, protected against DILI which was induced by the same three hepatotoxic agents used in the present study (10, 25, 36) ; thus, diminished CX32 levels caused by bortezomib treatment protect against DILI, and, on the contrary, the increased CX32 levels caused by MG132 are expected to exert opposite effects on DILI. Gap junction proteins are degraded by the proteasome system; thus, proteasome inhibition usually increases CX levels (45) (46) (47) . On the other hand, ER stress decreases CX43 expression at both the protein and mRNA levels by inhibiting CX43 promoter activity and accelerating the degradation of CX43 (48) . Therefore, we suggest that the balance between proteasome inhibition and induction of ER stress determines the effect of bortezomib on CX levels. Decreased bortezomib-induced CX32 levels also contribute to the protective effect on APAP-induced liver injury in addition to decreasing levels of CYP2E1 enzymatic activity.
Since bortezomib is currently being used in clinical settings, the protective effect of bortezomib on APAP-induced liver injury has clinical importance despite its unclear mechanism. Unfortunately, our study shows that bortezomib in mice was only effective when treatments longer than 3 h were used before APAP administration. Considering that the half-life of CYP2E1 protein is 6-7 h (41), the time needed for bortezomib to transcriptionally diminish CYP2E1 expression makes sense, but this finding weakens the practical usefulness of bortezomib as a treatment for DILI, since many patients need medical support when liver damage is already present (49) . Still, it is possible for bortezomib to be used to prevent DILI, as the use of high doses of some drugs known to be metabolised by CYP2E1 is clinically inevitable. In addition, bortezomib may help to increase the range of drug dosage, which may otherwise be limited due to DILI.
Proteasome inhibition has recently emerged as an effective therapeutic target in several human diseases. The present study suggests that proteasome inhibition has different effects with respect to DILI, depending on the specific drug employed. Bortezomib, but not MG132, was effectively used for alleviating drug-and chemical-induced liver injury in mice. Since ER stress, induced by proteasome inhibition, has distinct effects, each proteasome inhibitor should be individually scrutinised for its therapeutic applicability in future studies.
